Despite recent insider selling at Sonoco Products, shareholders need not worry deeply as insiders retain considerable company ownership, suggesting alignment with shareholders. Notably, the buying activity over the past year signals insider enthusiasm.
Sonoco's decent ROE comes with high debt levels, indicating risk. High ROEs without excessive debt denote good quality. Among companies with similar debt-to-equity ratios, a higher ROE is preferable.
Gapping up In reaction to earnings/guidance: •$New Relic(NEWR.US)$+3.8% (guidance),$美国航空(AAL.US)$+2% (guidance) Other news: •$DICE THERAPEUTICS, INC.(DICE.US)$+66.5% (announces "positive" topline data from its Phase 1 clinical trial of DC-806 an oral small molecule antagonist of the pro-inflammatory cytokine IL-17) •$Albireo Pharma(ALBO.US)$+17.2% (reports positive topline data from Phase 3 Trial of Bylvay (odevix...
Sonoco Products股票讨论区
Gap Ups
1. $Oak Street Health(OSH.US)$ -up 26.6%
2. $百度(BIDU.US)$ -up 7.5%
3. $英国石油(BP.US)$ -up 3.2%
4. $Fiserv(FISV.US)$ -up 2.4%
5. $三菱日联金融(MUFG.US)$ -up 1.4%
6. $葛兰素史克(GSK.US)$ -up 0.8%
7. $微软(MSFT.US)$ -up 0.7%
8. $赛诺菲安万特(SNY.US)$ -up 0.5%
9. $Activision Blizzard(ATVI.US)$ -up 0.4%...
In reaction to earnings/guidance:
• $New Relic(NEWR.US)$ +3.8% (guidance), $美国航空(AAL.US)$ +2% (guidance)
Other news:
• $DICE THERAPEUTICS, INC.(DICE.US)$ +66.5% (announces "positive" topline data from its Phase 1 clinical trial of DC-806 an oral small molecule antagonist of the pro-inflammatory cytokine IL-17)
• $Albireo Pharma(ALBO.US)$ +17.2% (reports positive topline data from Phase 3 Trial of Bylvay (odevix...
• $Coupang(CPNG.US)$ : Credit Suisse Upgrades to Outperform from Neutral - PT $19 (from $28)
• $First Republic Bank(FRC.US)$ : Atlantic Equities Upgrades to Overweight from Neutral - PT $188 (from $210)
• $Sitio Royalties(STR.US)$ : RBC Capital Upgrades to Outperform from Sector Perform - PT $43 (from $36)
Downgrades
• $Duck Creek Technologies(DCT.US)$ : JMP Securities Downgrades to Market Perform from Market Outperform
•...
• $La-Z-Boy(LZB.US)$ +9.3% (In reaction to earnings/guidance)
• $Enanta Pharmaceuticals(ENTA.US)$ +6.7% (ENTA files patent infringement lawsuit against $辉瑞(PFE.US)$)
• $Ikena Oncology(IKNA.US)$ +6.6% (granted Fast Track designation for IK-930)
• $BridgeBio Pharma(BBIO.US)$ +6.4% (Announces Early Positive Data for BBP-812)
• $Krystal Biotech(KRYS.US)$ +5% (submits Biologies License Application to FDA seeking approval of B-V...
暂无评论